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Abstract
Background: Aim of the study is to evaluate the role of ultrasound guided fine needle aspiration cytology (FNAC)
in the restaging of node positive breast cancer after preoperative systemic therapy (PST).
Methods: From January 2016 – October 2020 106 node positive stage IIA-IIIC breast cancer cases undergoing PST
were included in the study. 18 (17 %) were carriers of pathogenic variant in BRCA1/2. After PST restaging of axilla
was performed with ultrasound and FNAC of the marked and/or the most suspicious axillary node. In 72/106 cases
axilla conserving surgery and in 34/106 cases axillary lymph node dissection (ALND) was performed.
Results: False Positive Rate (FPR) of FNAC after PST in whole cohort and BRCA1/2 positive subgroup is 8 and 0 %
and False Negative Rate (FNR) – 43 and 18 % respectively. Overall Sensitivity − 55 %, specificity- 93 %, accuracy 70 %.
Conclusion: FNAC after PST has low FPR and is useful to predict residual axillary disease and to streamline surgical
decision making regarding ALND both in BRCA1/2 positive and negative subgroups. FNR is high in overall cohort
and FNAC alone are not able to predict ypCR and omission of further axillary surgery. However, FNAC performance
in BRCA1/2 positive subgroup is more promising and further research with larger number of cases is necessary to
confirm the results.
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Background
According to recent studies pathological complete re-
sponse (pCR) after neoadjuvant chemotherapy (NAC) in
node positive breast cancer is observed in up to 40–75 %
of cases [1–4]. BRCA1 positive breast cancer subgroup
also has high rate of pCR – up to 61 % [5]. It means that
preoperative systemic therapy has completely eliminated
all regional cancer involvement and total removal of all
axillary lymph nodes is not justified. However, until re-
cently axillary lymph node dissection (ALND) was per-
formed in all node positive cases irrespective of response
to PST. According to latest NCCN guidelines for breast
cancer, conservation of axilla should be considered, if
nodes are clinically negative after PST, but optimal axil-
lary management after PST is still not known [6, 7]. Sev-
eral preoperative and intraoperative axillary reevaluation
approaches have been studied recently including physical
examination, imaging (e.g. ultrasound, PET-CT) and bi-
opsy techniques [8, 9]. Imaging studies of PET/CT is
controversial for axillary staging after PST [10]. Com-
bined clipped and sentinel node biopsy approach has
very low false negative rate 1,4 %, but disadvantage is ne-
cessity of intraoperative frozen section and/or potential
for repeated axillary surgery in cN2 and cN3 cases [9].
FNAC or core needle biopsy has been widely used for
initial evaluation of axillary nodal status in case of breast
cancer, but to the best of our knowledge there are only
two small series (including our earlier one), which are
reporting on axillary lymph node FNAC accuracy after
PST [11, 12]. Aim of the study is to further evaluate the
role of FNAC in the restaging of node positive breast
cancer after PST, including subgroup of BRCA1/2 posi-
tive cases.
Materials and methods
Prospective cohort study was carried out at the state ter-
tiary healthcare institution. This study was approved by
the Pauls Stradiņš Clinical Univerity hospital Develop-
ment Society Clinical Research Ethics Committee
(310816-12 L) and Riga Stradiņš University Research
Ethics Committe (72/29.10.2015.) All participants pro-
vided written informed consent.
From January 2016 – October 2020 106 FNAC con-
firmed node positive stage IIA-IIIC breast cancer cases
undergoing PST were recruited to the study, including
18 (17 %) carriers of pathogenic variant in BRCA1 (2-
300T > G, 5- 4154delA, 7-5382insC, 2- c.5117G > A, 1-
del exon20) and BRCA2 (1- 9097delA). All patients were
female with median age of 51 years (range 25–75 years).
18/106 (17 %) of cases belonged to HER2 positive sub-
type, 24/106 (23 %) were triple negative (TN) and 64/
106 (60 %) Luminal. 17/106 (16 %) cases were Luminal
HER2 positive. Cases are considered as TN if HER2 is
negative and estrogen/progesteron is < 10 %. 100/106
(94 %) had ductal, 5/106 (5 %) cases - lobular and 1/106
(1 %) combined pathology.
According to study protocol both before and after PST
fine needle aspiration (FNA) was performed if at least
one lymphnode on ultrasound had cortex > 3mm or ab-
sence of fatty hilum was present irrespective of lymph-
node size. In case of several lymphnodes with the
suspicious features, one with the most prominent
changes and/or the most accessible from technical per-
spective was chosen.
FNA procedure was performed following the tech-
nique described by Dusenbery, 1997. Once the needle
was in lymphnode, suction was applied to the syringe
and the needle tip was moved back and forth within the
node. On average 10 to 20 excursions with the needle
were performed before obtaining material in the hub of
the needle.
In case of malignant finding in cytology, marker was
introduced in affected lymphnode to facilitate restaging
and targeted surgery of axilla. Initially V-mark™ Breast
Biopsy Site Marker with Titanium Anchor (Argon Med-
ical Devices, Inc) were used, but later were changed to
Hydromark clips, which have better visualization capaci-
ties under ultrasound at least 6 months after insertion.
Targeted axillary ultrasound and FNA was carried out
by three general surgeons with the specialization in
breast surgery, who have successfully passed EBSQ
(European Breast Surgery Qualification) exam and have
underwent National Ultrasound method postgraduate
courses. In all cases sampling was done by the same
physician before and after PST. All samples were
reviewed by one cytologist experienced in breast
pathology.
cN stage was diagnosed on the basis of pretreatment
imaging (ultrasound and CT) data. If 1–3 involved axil-
lary nodes were identified – cN1 stage was classified. If
more than 3 metastatic lymph nodes were visualized in
axilla, then cN2 stage was set. If infra/supraclavicular
lymph node metastasis or more than 10 affected axillary
nodes were detected, then cN3 stage was diagnosed. Fre-
quency of cN1, cN2 and cN3 stage was observed in 58
(55 %), 23 (22 %) and 25 (23 %) cases respectively.
After PST restaging of axilla was performed with ultra-
sound guided FNAC of the marked and/or the most sus-
picious axillary node. Nondiagnostic cases were not
included. In 10/106(9 %) cases, deviation from study
protocol took place as core biopsy technique was used
instead of FNAC.
Modified algorithm of Netherlands cancer institute/
Antoni van Levenhoek hospital (NCI/AVL) was followed
to decide on axilla conserving surgery (ACS) versus
ALND as described by Koolen [4]. 72/106 axilla conserv-
ing surgeries (ACS) and 34/106 ALND were performed.
Number of examined nodes in ACS group was 1–18, on
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average 6 and in ALND group 2–30, on average 13. Dif-
ference between retrieved nodes in ACS and ALND was
statistically significant (p < 0.05).
In order to assess diagnostic value of ultrasound
guided FNAC, FNR and FPR as well sensitivity, specifi-
city, positive predictive value (PPV), negative predictive
value (NPV) and accuracy were calculated. Statistical
analyses were performed using Medcalc, easy-to-use
software and MS Excel 2010. Fisher’s exact test was used
for comparison of the results between groups.
Results
Overall nodal pCR was observed in 41/106 (39 %) cases:
Luminal − 19/64 (30 %); HER2 positive – 11/18 (61 %);
TN – 11/24 (46 %). Distribution of nodal pCR in
BRCA1/2 positive and negative subsets is -9/18(50 %)
and 32/88 (36 %) respectively.
After PST FNAC revealed residual nodal cancer in 39/
106 (37 %) cases, but in 67/106 (63 %) no malignancy
was detected. In final surgical pathology in 65/106
(61 %) cases malignant cells persisted in axillary lymph
nodes, but in 41/106 (39 %) cases no nodal tumor was
detected after PST.
In 36/39 (92 %) cases, which had positive FNCA after
PST, metastasis in axillary lymph nodes were revealed in
the pathology examination of surgery specimen - ypN1mi,
ypN1, ypN2 and ypN3 stage was detected in 1, 18, 11 and
6 cases respectively. Overall FPR of FNAC after PST is 3/
39 (8 %). In contrary, only 38/67(57 %) cases with negative
lymph node FNAC after PST, turned out to be without
nodal involvement in surgery specimen examination. 29
false negative cases in final pathology revealed ypNmi,
ypN1, ypN2, ypN3 nodal status in 7, 18, 3 and 1 case re-
spectively. Overall FNR of FNCA after PST is 29/67
(43 %). FNAC was able to predict nodal response to PST
correctly in 74/106 (70 %) of cases.
Further subgroup analysis revealed that in case of
BRCA1/2 positive breast cancers FPR was 0 % (0/7) and
FNR was 18 % (2/11). In this subset FNAC was able to
predict response to PST correctly in 16/18 (89 %) cases.
Comparison of FNR between BRCA1/2 positive and
BRCA1/2 negative subsets using Fisher’s exact test
revealed statistical difference very close to significant, p
value = 0,051502, but difference between FNR in
BRCA1/2 positive and Luminal subsets was statistically
significant, p = 027096.
Accuracy of FNAC test in TN, HER2 positive,
Luminal and BRCA1/2 negative subgroups is 79 %,
78 %, 64 and 66 % respectively. Detailed results of
FPR, FNR, sensitivity, specificity, positive and negative
predictive value as well accuracy of the test in differ-
ent subgroups see in Table 1.
Discussion
Axillary pCR after PST is frequent event in case of
breast cancer [1–4]. Also, in our cohort we report 39 %
of axillary pCR. Therefore, it is very important to per-
form appropriate restaging in node positive breast can-
cers after PST to avoid unnecessary ALND. One has to
take in to account that there is no pertuzumab approved
for PST in nonmetastatic setting in our country and with
dual HER2 blockade pCR rate is expected to be even
higher.
ACS, including clipped node biopsy alone or in com-
bination with SNB has very low FNR [4, 9] and is very
good approach to restage the axilla after PST, however
in large proportion of node positive cases, especially cN2
and cN3 stage, still considerable residual nodal involve-
ment remains, which requires ALND. One solution is
frozen section, but it has several disadvantages: poten-
tially prolonged surgery time and rather high FNR –
33 % [13]. It means that considerable proportion of cases
potentially could require repeated surgery to perform
ALND and it is not ideal management neither from pa-
tient nor hospital perspective. Therefore, it is important
to have accurate diagnostic tools for axilla restaging
preoperatively.
There are data on effectiveness of axillary ultrasound
and FNAC to evaluate nodal status prior breast cancer
treatment as well evaluation of ultrasound method alone
after PST [14, 15]. However to the best of our knowledge
there are only two small series (including our earlier one),
which are reporting on axillary lymph node FNAC accur-
acy after PST [11, 12]. In our present study false negative
Table 1 FPR, FNR, sensitivity, specificity, positive and negative predictive value as well accuracy of the FNAC test
Overall BRCA Non BRCA TN HER2+ Luminal
FPR% 8 (3/39) 0 (0/7) 9 (3/32) 0 (0/8) 0 (0/3) 11 (3/28)
FNR% 43 (29/67) 18 (2/11) 48 (27/56) 31 (5/16) 27 (4/15) 56 (20/36)
Sensitivity% 55.38 77.78 51.79 61.54 42.86 55.56
Specificity% 92.68 100 90.62 100 100 84.21
Positive Predictive Value% 92.31 100 90.63 100 100 89.29
Negative Predictive Value% 56.72 81.82 51.79 68.75 73.33 44.44
Accuracy% 69.81 88.89 65.91 79.17 77.78 64.06
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rate of FNCA after PST is 43 %, sensitivity – 55.38 % and
negative predictive value – 56.72 %. False positive rate is
8 % and specificity of the test is 92.68 %. Accuracy of test
is 69.81 %. Obtained data are similar to those reported by
Caudle et al.: sensitivity of 42.4 %, specificity of 100 %, and
negative predictive value of 40.6 %. In the studies, which
have evaluated the diagnostic value of axillary FNAC prior
to PST, reported sensitivity, specificity and accuracy lies
between 41 and 80%, 96-100 % and 70–89 % respectively,
but methodological differences exist [16–22]. We can con-
clude that in our study sensitivity of the FNAC is close to
lowest range reported, but specificity and accuracy is
clearly lower. One can conclude that accuracy of axillary
FNAC after PST is somewhat lower than prior to PST.
Low sensitivity of axillary FNAC together with high FNR
in this setting precludes the omission of axillary surgery in
spite of negative cytology. However, low FPR and specifi-
city of the test is high enough to streamline surgical care
with ALND for node-positive patients with considerable
residual cancer burden expected. This approach has a po-
tential to avoid frozen section and repeated axillary sur-
gery in particular cases.
There are also report that sensitivity and specificity of
axillary ultrasound alone after PST are 55 and 88 %, re-
spectively, which is very close to results of our research
[23–25]. However pathological confirmation of ycN
stage is very important in surgical decision making espe-
cially taking in to account that ultrasound method is
highly operator dependent.
In spite of high overall FNR, it is considerably lower in
BRCA1/2 positive subgroup in comparison to BRCA1/2
negative subgroup (18 % vs. 48 %). This difference is very
close to reach statistical significance and difference be-
tween FNR in BRCA1/2 positive and Luminal subgroups
(18 % vs. 56 %) is statistically significant. Reasons for this
potential finding are not completely clear, but could be
related to the more homogenous patterns of nodal re-
sponse to PST in case of BRCA1/2 carriers. However
larger numbers are required to confirm this finding and
potential for omission of axillary surgery in this sub-
group on the basis of percutaneous biopsy only.
Like other studies we report significantly lower axillary
pCR rate in Luminal subtype breast cancers [1]. Lobular
breast cancers have extremely low rates of pCR after
PST, but there are only 5/106 lobular cancer cases in
our cohort and we are not into position to make any
statements on this [26].
One of the potential biases of the study is inclusion
of small number of core needle biopsy cases as well.
For a short period of time it was allowed for respon-
sible surgeon to choose between FNAC or core nee-
dle biopsy. However, according to literature data
there is no considerable diagnostic value differences,
but we presume that CNB is associated with smaller
percentage of uninformative samples and repeated
procedures respectively [27].
Another potential cause of bias - interobserver vari-
ability should be mentioned [28].
Present literature evidence continues to recommend
FNAC as the most sensitive screening for breast cancer
metastases in the axillary region. However, one should
also mention innovative vacuum assisted breast biopsy
(VABB) technologies, which could be considered in fu-
ture studies. To the best of our knowledge there are no
literature date on the use of this method to evaluate axil-
lary lymph nodes after PST [29].
There are also number of calculation tools available to pre-
dict status of sentinel node in case of breast cancer with clin-
ically negative axilla. However, as showed by experimental
results by Fanizzi et al., CancerMath is not particularly suit-
able for use as a support instrument for the prediction of
metastatic lymph nodes on clinically negative patients. And
again, it should be emphasized that those tools are not vali-
dated in patients after PST, which is the target group of our
study [30].
In our research we used only Gray-scale ultrasound.
To improve gray-scale ultrasound results, some of the
authors offer to use contrast-enhanced ultrasound
(CEUS), elastography or colour Doppler. A systematic
review and meta-analysis shows CEUS-guided core bi-
opsy sensitivity 54 % and specificity 100 % in cases with
normal axillary gray-scale ultrasound [31].
In another study grey-scale ultrasound was compared
to elastography. Sensitivity and specificity for grey-scale
ultrasound in detecting malignant nodes (defined by a
cortical thickness > 3 mm) were 40 and 97 %. Sensitivity
and specificity for elastography were 60 and 80 %. When
grey-scale ultrasound and elastography were combined,
the sensitivity and specificity rose to 73 and 99 %, re-
spectively [32].
In spite of controversial reports, there are number of
additional tools to be considered for future studies to
improve axillary restaging after PST [33].
Conclusions
FNAC after PST has low FPR and is useful to predict re-
sidual axillary disease and to streamline surgical decision
making regarding ALND both in BRCA1/2 positive and
negative subgroups. FNR is high in overall cohort and
FNAC alone are not able to predict ypCR and omission
of further axillary surgery. However, FNAC performance
in BRCA1/2 positive subgroup is more promising and
further research with larger number of cases is necessary
to confirm the results.
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